Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection
NCT ID: NCT00002051
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thymopentin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Allowed:
* Aerosolized pentamidine.
Prior Medication:
Allowed:
* Aerosolized pentamidine.
Exclusion Criteria
Patients with the following are excluded:
* AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
* Significant hepatic disease.
* Thrombocytopenia (\< 75000 platelets/mm3).
* Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to entry.
* Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
* Known hypersensitivity to thymopentin.
Prior Medication:
Excluded within 30 days of study entry:
* Immunomodulatory or experimental therapy.
* Excluded within 90 days of study entry:
* Zidovudine (AZT).
Patients must not have:
* AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
* Significant hepatic disease.
* Thrombocytopenia (\< 75000 platelets/mm3).
Patients with the following conditions are included:
* Seropositive for HIV-1 (ELISA assay) confirmed by Western blot.
* HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's peripheral blood monocytes (PBMC) on two separate occasions.
* HIV "wasting syndrome".
* Must voluntarily sign consent.
History of intravenous drug abuse.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Immunobiology Research Institute
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Immunobiology Research Institute
Annandale, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H87-101
Identifier Type: -
Identifier Source: secondary_id
015E
Identifier Type: -
Identifier Source: org_study_id